Glucose-lowering drugs or strategies reduce the risk for major adverse cardiovascular events and death in people with or at risk for type 2 diabetes, but their impact on heart failure may depend on weight loss, shows an updated systematic review and meta-analysis.
The addition of rivaroxaban to aspirin results in a similar relative reduction in the risk for cardiovascular events among patients with stable atherosclerosis and a history of atherosclerotic disease regardless of whether or not they have diabetes, suggests a subgroup analysis of the COMPASS trial.
Treatment with dapagliflozin is associated with a significant reduction in the risk for heart failure worsening or cardiovascular death in people with heart failure and reduced ejection fraction regardless of whether or not they have diabetes, shows an exploratory analysis of DAPA-HF trial data.
More than half of people with coronary artery disease have impaired glucose tolerance, yet many are unaware of this or are undertreated despite knowledge of their condition, results of the EUROASPIRE V survey show.
An analysis of percutaneous coronary intervention outcomes among people with rheumatic diseases suggests that those with systemic sclerosis have an elevated risk for multiple in-hospital complications, while patients with systemic lupus erythematosus have an increased bleeding risk.
Children born to mothers with diabetes have a higher risk for early-onset, non-congenital cardiovascular disease in childhood and early adulthood than those born to mothers without diabetes, suggest findings from a large observational study.
Survivors of the 20 most common site-specific cancers, including lung and prostate, are at increased risk for cardiovascular disease in the years that follow diagnosis and treatment, show data published in The Lancet.
Findings from the THEMIS trial suggest that the addition of ticagrelor to aspirin treatment reduces the incidence of ischemic cardiovascular events among people with type 2 diabetes and stable coronary artery disease, but at the cost of an increased risk for major bleeding, resulting in an unfavorable risk:benefit ratio.
People with osteoarthritis have a significantly higher risk for developing cardiovascular disease than those without, and the use of nonsteroidal anti-inflammatory drugs mediates a considerable proportion of this association, researchers report.
Findings from the SAVOR-TIMI 53 trial suggest that metformin treatment reduces cardiovascular and all-cause mortality but not nonfatal cardiovascular disease events, but a meta-analysis points to wider benefits.
People with osteoarthritis are significantly more likely than those without to have multiple comorbidities, particularly stroke, peptic ulcers, and the metabolic syndrome, show results of a systematic review and meta-analysis of observational data.
Patients with locally advanced non-small-cell lung cancer have a high risk for major adverse cardiac events after radiotherapy that may warrant a reduction in cardiac radiation dose, study findings indicate.
Increased atherosclerotic plaque burden, as estimated by carotid ultrasound, is associated with an increased risk for cardiovascular events in patients with psoriatic disease, Canadian researchers report.
People with diabetes and stable ischemic heart disease are more likely to have long-term survival when they have a greater number of risk factors controlled at prespecified therapeutic goals, research shows.
Among men initiating abiraterone acetate for advanced prostate cancer, the mortality risk may be higher for those with versus without pre-existing cardiovascular disease, suggests a real-world study presented at the AACR Annual Meeting 2019 in Atlanta, Georgia, USA.